|
[1]徐道振.病毒性肝炎临床实践[M].北京:人民卫生出版社.2006∶9.
|
|
[2] 中华医学会.病毒性肝炎防治方案[J].中华肝脏病杂志, 2000, 8∶324-329.
|
|
[3]孙庆丰, 吕勇, 徐道振, 等.乙型肝炎病毒e抗原及DNA载量对慢性乙型重型肝炎预后的影响[J].中华肝脏病杂志, 2006, 14 (6) ∶410-413.
|
|
[4]吴云忠, 赵凤林, 张春泽, 等.慢性重型乙型肝炎转归相关因素及抗病毒治疗研究[J].中华实验和临床病毒学杂志, 2007, 21.
|
|
[5]中华医学会.肝衰竭诊疗指南[J].中华肝脏病杂志, 2006, 14 (9) ∶643-646.
|
|
[6]王融冰, 孙凤霞, 吴璐, 等.拉米夫定治疗HBV DNA阳性的慢性重型肝炎的临床分析[J].肝脏, 2002, 7 (2) ∶101.
|
|
[7]Tsubota A.Lamivudine therapy for spontaneously occurring severe a-cute exacerbation in chronic hepatitis B virus infection:a preliminarystudy[J].Am J Gastroenterol, 2001, 96 (2) ∶557-62.
|
|
[8]Tsang SW.Lamivudine treatment for fulminant hepatic failure due toacute exacerbation of chronic hepatitis B infection[J].Aliment Phar-macol Ther, 2001, 15 (11) ∶1737-44.
|
|
[9]Anna SL, Fabien Z, Stephen L, et al.Antiviral drug-resistantHBV:Standardization of nomenclature and assays and recommenda-tions for management[J].Hepatology, 2007, 46 (1) ∶254-265.
|
|
[10]Ting-Tsung C, Robert G, Robert D M, et al.Acomparison of En-tecavir and Lamivudine for HBeAg-positive chronic hepatitis B[J].N Engl J Med, 2006, 354∶1001-10.
|
|
[11]Guangbi Ya.Entecavir is a potent anti-HBVdrug superior to lami-vudine:experience from clinical trials in China[J].Journal of Anti-microbial Chemotherapy, 2007, 60∶201-205.
|
DownLoad: